Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.

TitleDependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma.
Publication TypeJournal Article
Year of Publication2019
AuthorsPrutsch N, Gurnhofer E, Suske T, Liang HChang, Schlederer M, Roos S, Wu LC, Simonitsch-Klupp I, Alvarez-Hernandez A, Kornauth C, Leone DA, Svinka J, Eferl R, Limberger T, Aufinger A, Shirsath N, Wolf P, Hielscher T, Sternberg C, Aberger F, Schmoellerl J, Stoiber D, Strobl B, Jäger U, Staber PB, Grebien F, Moriggl R, Müller M, Inghirami GG, Sanda T, A Look T, Turner SD, Kenner L, Merkel O
JournalLeukemia
Volume33
Issue3
Pagination696-709
Date Published2019 03
ISSN1476-5551
KeywordsAnaplastic Lymphoma Kinase, Animals, Apoptosis, Cell Line, Tumor, Cell Survival, Gene Expression Regulation, Neoplastic, Humans, Lymphoma, Large-Cell, Anaplastic, Mice, Myeloid Cell Leukemia Sequence 1 Protein, Phosphorylation, Protein Kinase Inhibitors, Protein-Tyrosine Kinases, Signal Transduction, STAT1 Transcription Factor, STAT3 Transcription Factor, Translocation, Genetic, TYK2 Kinase
Abstract

TYK2 is a member of the JAK family of tyrosine kinases that is involved in chromosomal translocation-induced fusion proteins found in anaplastic large cell lymphomas (ALCL) that lack rearrangements activating the anaplastic lymphoma kinase (ALK). Here we demonstrate that TYK2 is highly expressed in all cases of human ALCL, and that in a mouse model of NPM-ALK-induced lymphoma, genetic disruption of Tyk2 delays the onset of tumors and prolongs survival of the mice. Lymphomas in this model lacking Tyk2 have reduced STAT1 and STAT3 phosphorylation and reduced expression of Mcl1, a pro-survival member of the BCL2 family. These findings in mice are mirrored in human ALCL cell lines, in which TYK2 is activated by autocrine production of IL-10 and IL-22 and by interaction with specific receptors expressed by the cells. Activated TYK2 leads to STAT1 and STAT3 phosphorylation, activated expression of MCL1 and aberrant ALCL cell survival. Moreover, TYK2 inhibitors are able to induce apoptosis in ALCL cells, regardless of the presence or absence of an ALK-fusion. Thus, TYK2 is a dependency that is required for ALCL cell survival through activation of MCL1 expression. TYK2 represents an attractive drug target due to its essential enzymatic domain, and TYK2-specific inhibitors show promise as novel targeted inhibitors for ALCL.

DOI10.1038/s41375-018-0239-1
Alternate JournalLeukemia
PubMed ID30131584
PubMed Central IDPMC8076043
Grant ListP 27132 / FWF_ / Austrian Science Fund FWF / Austria
14856 / / Oesterreichische Nationalbank (Austrian National Bank) / International
Related Faculty: 
Giorgio Inghirami, M.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700